Table 1.

Analysis of six randomized controlled trials reporting measures of spasticity after THC-CBD treatment

	Killestein 2002 [15]	Wade 2003 [17]	Zajicek 2003 [16]	Wade 2004 [19]	Vaney 2004 [18]	Collin 2007 [20]
Design	Crossover	Crossover	Parallel	Parallel	Crossover	Parallel
Jaded score	4	4	5	5	5	4
Study objective	Small study to compare effects of THC and THC-CBD	Pilot study to explore benefits for neurogenic symptoms	Large study to compare effects of THC and THC-CBD	Benefits over a range of symptoms	Effects on spasm frequency	Effects on spasticity
Sample size	16	14	395 (198 placebo)	154 (77 placebo)	57	184 (64 placebo)
Duration	4 weeks	4 weeks	15 weeks	6 weeks	2 weeks	6 weeks
Intervention	THC-CBD <10 mg daily	THC-CBD 2.5-120 mg daily	THC-CBD <25 mg daily	THC-CBD <120 mg daily	THC-CBD <30 mg daily	THC-CBD >25 mg daily
Ashworth score
Mean change	App. -.3	No change	1.24	-0.37	-2.2	-0.64
P-value	Not significant	>0.05	0.29	0.22	0.002	0.218
VAS spasticity			Not reported		Not reported	Not reported
Mean change	No change	Reduced 14.9 points		Reduced 31.2 points
P-value	Not significant	<0.05		0.001
Walk time	Not reported	Not reported			Not reported	Not reported
Mean change			Reduced 4%	Reduced 2.78 (s)
P-value			Not reported	0.07
RMI	Not reported			Not reported		Not reported
Mean change		Improved 0.2	Improved 0.4		Improved 0.5
P-value		>0.05	0.21		0.005
Self-reported rating
Measure	Global impression VAS	Numerical symptom scale	Category rating scale	Diary entry VAS scale	Spasm frequency scale	Numerical rating scale
Mean change	Worsened	Frequency reduced 1.9; severity reduced 2.1	52% treated reported improvement	Frequency score reduced 21.41; severity reduced 21.67	Reduced 0.4	Reduced 1.18
P-value	0.02	<0.05	0.01	0.009	<0.001	0.048
Adverse events	41 reported, none serious	16 reported	12 serious reported	4% withdrawn	No serious reported	4.8% withdrawn

RMI, Rivermead Mobility Index; VAS, Visual Analogue Scale.